Your session is about to expire
← Back to Search
Magnesium sulfate for Esophageal Disorders (MgPOEM Trial)
MgPOEM Trial Summary
This trial found that magnesium may help reduce postoperative pain and the amount of opioids needed after surgery for peroral endoscopic myotomy.
- Spastic Esophageal Disorders
MgPOEM Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMgPOEM Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MgPOEM Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
In what situations is Magnesium sulfate usually administered?
"Magnesium sulfate is the gold standard for treating hypomagnesemia, but it has also been successful in combating poisoning, prophylaxis of hypomagnesemia, and contusions."
Are there any remaining vacancies for participants in this clinical research?
"As per clinicaltrials.gov, this medical trial is currently enrolling patients and has been active since December 28th 2020 with the most recent edit being made on June 10th 2021."
Is Magnesium sulfate an innocuous substance for humans?
"Magnesium sulfate is rated a 2 on the scale of 1 to 3. This score indicates that while there are some data collected in regard to its safety, no clinical studies have been completed yet to attest efficacy."
Is there any extant research that utilizes Magnesium sulfate?
"Presently, 27 experiments are investigating the therapeutic potential of Magnesium sulfate. Out of those trials, 8 have advanced to Phase 3. The majority are located in Guangzhou and other parts of Guangdong, totaling 42 locations altogether."
How many people have been invited to partake in this experiment?
"Affirmative. According to the details hosted on clinicaltrials.gov, this medical experiment began recruiting patients in December of 2020 and is still actively doing so today as per its last update on June 10th 2022; they are looking for 100 participants at 1 site."
Share this study with friends
Copy Link
Messenger